- Adherence among chronic disease patients can lead to big savings
- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Decision Resources: Bydureon could promote weight loss among patients
- Community-based healthcare models can help diabetic patients
- Study: Hemoglobin A1C may not effectively diagnose kids with diabetes
DEERFIELD, Ill. — Three new drugs for Type 2 diabetes made by Takeda Pharmaceutical Co. have become available in pharmacies, the company said.
The drug maker announced the availability of Nesina (alogliptin), Kazano (alogliptin; metformin hydrochloride) and Oseni (alogliptin; pioglitazone).
"Diabetes is an increasingly complex disease, and many patients require treatment to be individualized to their needs," Takeda Pharmaceuticals USA senior director for diabetes and obesity marketing Jennifer Greeby said. "The availability of Nesina, Kazano and Oseni marks an important milestone in Takeda's commitment to patients living with Type 2 diabetes and provides new options for physicians."